Literature DB >> 25023240

[Prostate biopsy. Update for indication, procedure, and future developments].

S Machtens1, A Roosen, C G Stief, M C Truß.   

Abstract

Transrectal ultrasound-guided prostate biopsy is considered the gold standard in the primary investigation of a suspicious prostate-related finding. The procedure can be carried out with ten probes or more on the lateral side of the prostate, after administering antibiotic prophylaxis and applying local anesthesia. The indication for a biopsy depends on the results of the digitorectal examination, on the serum prostate-specific antigen level, on the individual patient's wish and on his comorbidities. Whether multiparametric imaging should be used before or during the course of a primary or repeated biopsy in order to identify suspicious prostate lesions is the subject of current investigations. Extended biopsy protocols require further clinical investigations before they can become the new standard in the diagnostic work-up. This review delivers an update on the indication for, and technique of, prostate biopsies.

Entities:  

Mesh:

Year:  2014        PMID: 25023240     DOI: 10.1007/s00120-014-3536-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  40 in total

1.  NCCN clinical practice guidelines in oncology: prostate cancer early detection.

Authors:  Mark H Kawachi; Robert R Bahnson; Michael Barry; J Erik Busby; Peter R Carroll; H Ballentine Carter; William J Catalona; Michael S Cookson; Jonathan I Epstein; Ruth B Etzioni; Veda N Giri; George P Hemstreet; Richard J Howe; Paul H Lange; Hans Lilja; Kevin R Loughlin; James Mohler; Judd Moul; Robert B Nadler; Stephen G Patterson; Joseph C Presti; Antoinette M Stroup; Robert Wake; John T Wei
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

2.  Systematic transperineal ultrasound-guided template biopsy of the prostate: three-year experience.

Authors:  David M Pinkstaff; Todd C Igel; Steven P Petrou; Gregory A Broderick; Michael J Wehle; Paul R Young
Journal:  Urology       Date:  2005-04       Impact factor: 2.649

3.  Significant ecological impact on the progression of fluoroquinolone resistance in Escherichia coli with increased community use of moxifloxacin, levofloxacin and amoxicillin/clavulanic acid.

Authors:  Oscar Cuevas; Jesús Oteo; Edurne Lázaro; Belén Aracil; Francisco de Abajo; Silvia García-Cobos; Adriana Ortega; José Campos
Journal:  J Antimicrob Chemother       Date:  2010-12-14       Impact factor: 5.790

Review 4.  Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?

Authors:  Carsten Stephan; Thomas Köpke; Axel Semjonow; Michael Lein; Serdar Deger; Mark Schrader; Kurt Miller; Klaus Jung
Journal:  Clin Chem Lab Med       Date:  2009       Impact factor: 3.694

5.  Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.

Authors:  René Raaijmakers; Mark F Wildhagen; Kazuto Ito; Alvaro Pàez; Stijn H de Vries; Monique J Roobol; Fritz H Schröder
Journal:  Urology       Date:  2004-02       Impact factor: 2.649

6.  Diagnosis of "suspicious for malignancy" in prostate biopsies: predictive value for cancer.

Authors:  K A Iczkowski; T J Bassler; V S Schwob; I C Bassler; B S Kunnel; R E Orozco; D G Bostwick
Journal:  Urology       Date:  1998-05       Impact factor: 2.649

7.  What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels?

Authors:  Stacy Loeb; William J Catalona
Journal:  Nat Clin Pract Urol       Date:  2009-01-13

8.  Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.

Authors:  Matthew Frank O'Brien; Angel M Cronin; Paul A Fearn; Brandon Smith; Jason Stasi; Bertrand Guillonneau; Peter T Scardino; James A Eastham; Andrew J Vickers; Hans Lilja
Journal:  J Clin Oncol       Date:  2009-06-08       Impact factor: 44.544

9.  Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy.

Authors:  Gary Onik; Winston Barzell
Journal:  Urol Oncol       Date:  2008 Sep-Oct       Impact factor: 3.498

10.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.